BJH - volume 14, issue 2, march 2023
I. Moors MD, D. Deeren MD, C. Jacquy MD, PhD, A. Jaspers MD, PhD, T. Kerre MD, PhD, V. Havelange MD, PhD, D. Selleslag MD, C. Spilleboudt MD, N. Straetmans MD, PhD, F. Van Obbergh MD, A. De Voeght MD, S. Anguille MD, PhD, A. Schauwvlieghe MD, PhD, N. De Beule MD, PhD, A. De Becker MD, D. Breems MD, PhD
Acute myeloid leukaemia is an aggressive form of bone marrow cancer with poor prognosis, especially in elderly, unfit patients. The VIALE-A study showed an impressive improvement in complete remission rate and overall survival with the addition of venetoclax, a BCL-2 inhibitor, to azacitidine. This combination therapy is now reimbursed in Belgium for newly diagnosed adult AML patients who are considered unfit for intensive chemotherapy based on age and/or comorbidities. In this article, we provide recommendations on the use of this new combination, as well as on prophylaxis and management of specific side effects.
(BELG J HEMATOL 2023;14(2):59–66)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
F. Van Obbergh MD, N. Vanlangendonck , A. Van Maanen , P. Van Muylder , A. Ferrant , C. Lambert MD, PhD, E. Van den Neste MD, PhD, D. Latinne , X. Poiré MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
F. Van Obbergh MD, L. Knoops MD, PhD, Y. Beguin MD, PhD, C. Graux MD, PhD, S. Benghiat MD, PhD, K. Kargar-Samani , D. Bauwens , A. Efira MD, C. Dubois , C. Springael MD, PhD, L. Montfort , T. Connerotte MD, A. Delannoy , P. Wallemacq
BJH - volume 6, issue Abstract Book BHS, january 2015
C. AL Assaf , F. Van Obbergh MD, J. Billiet MD, E. Lierman PhD, T. Devos MD, PhD, C. Graux MD, PhD, A.S. Hervent , T. Tousseyn MD, PhD, P. De Paepe MD, PhD, P. Papadopoulos , L. Michaux MD, PhD, P. Vandenberghe MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
F. Van Obbergh MD, A. Ferrant , D. Wilmes , J. Yombi , L. Knoops MD, PhD, M.C. Vekemans MD, L. Michaux MD, PhD
BJH - volume 4, issue 3, september 2013
F. Van Obbergh MD, A. Van Hoof MD, PhD, G. Verhoef MD, PhD, D. Dierickx MD, PhD, V. De Wilde MD, PhD, F. Offner MD, PhD, D. Bron MD, PhD, A. Sonet MD, M. André MD, PhD, A. Janssens MD, PhD, C. Bonnet MD, B. Deprijck MD, P. Zachée MD, PhD, A. Kentos MD, PhD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD
The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each panellist’s expert provided interpretation of the evidence, based on literature review and personal experience. The available evidence was systematically discussed prior to formulating recommendations. A systematic approach to obtain consensus of expert opinion was used. After each meeting, the draft guideline was circulated to all experts for comment and approval. The present guidelines focus on general management of peripheral T-cell lymphomas with special emphasis on more specific disease-adapted strategies.
(BELG J HEMATOL 2013;4(3):90–101)
Read moreBJH - 2013, issue BHS Abstractbook, january 2013
F. Van Obbergh MD, C. Lambert MD, PhD, O. Ciccarelli , C. Dangoisse , C. Sempoux , L. Knoops MD, PhD, A. Ferrant , L. Michaux MD, PhD, M.C. Vekemans MD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
